[Cited FineTest Elisa Kit] Current Research on Obesity and Metabolic Disorders

FineTest Elisa kit contributes to the research on obesity and metabolic disorders. The immunoassay is designed to measure T3(Triiodothyronine) concentration in serum.

Publication Details
Article Title: Adipose-targeted triiodothyronine therapy counteracts obesity-related metabolic complications and atherosclerosis with negligible side effects
Journal Title: Nature Communications
DOI: 10.1038/s41467-022-35470-4
IF: 17.694
PMID: 36539421

Abstract:     Thyroid hormone (TH) is a thermogenic activator with anti-obesity potential. However, systemic TH administration has no obvious clinical benefits on weight reduction. Herein we selectively delivered triiodothyronine (T3) to adipose tissues by encapsulating T3 in liposomes modified with an adipose homing peptide (PLT3). Systemic T3 administration failed to promote thermogenesis in brown and white adipose tissues (WAT) due to a feedback suppression of sympathetic innervation. PLT3 therapy effectively obviated this feedback suppression on adrenergic inputs, and potently induced browning and thermogenesis of WAT, leading to alleviation of obesity, glucose intolerance, insulin resistance, and fatty liver in obese mice. Furthermore, PLT3 was much more effective than systemic T3 therapy in reducing hypercholesterolemia and atherosclerosis in apoE-deficient mice. These findings uncover WAT as a viable target mediating the therapeutic benefits of TH and provide a safe and efficient therapeutic strategy for obesity and its complications by delivering TH to adipose tissue.

Keywords:   Adipocytes, Drug Therapy, Endocrine and Metabolic Disorders, Atherosclerosis

Immunoassay

Validated Image

Figure Source: Nat Commun. 2022 Dec 20;13(1):7838. doi: 10.1038/s41467-022-35470-4.

Fig. 1: Construction and evaluation of liposomal nanoparticles for adipose-selective drug delivery.